Good afternoon and welcome to Cantargia's presentation of the second quarter and first-half year report for 2026. My name is Hilde Steineger, Chief Executive Officer at Cantargia, and I'm joined today by our Chief Financial Officer, Patrik Renblad. Today, I will take you through the operational and strategic progress during the quarter, including our clinical development plans and pipeline priorities. Patrik will then present the financial results for the second quarter and the first six months of 2026 before I return with a brief summary. Then, we will open the floor for questions.
The central theme of today is how Cantargia continues to build on its leadership in IL1RAP antibody development, with nadunolimab as our lead oncology asset and with new opportunities emerging both in pancreatic cancer and hematologic malignancies. Next slide.
Before we begin, I would like to remind everybody that today's presentation contains forward-looking statements. Forward-looking statements. These statements are subject to risks and uncertainties, and actual results may differ from those expressed or implied. We therefore encourage you to read through the Safe Harbor statement and the risk factors described in Cantargia's public disclosures.
Next slide, please. Today's presentation will be structured in three parts. As mentioned, I will first summarize the key events and then review our pipeline. Next slide. The second quarter was a pivotal one for Cantargia, with meaningful progress on both the financial and clinical development fronts. First, we strengthened our balance sheet. A rights issue combined with a loan facility from venture capital delivered gross proceeds of 133. 32 million Swedish kronor.
This capital is earmarked for our key strategic clinical priorities for nadunolimab, most notably the planned combination study with a KRAS inhibitor, daraxonrasib, in pancreatic ductal adenocarcinoma, or PDAC. Second, we extended nadunolimab's clinical footprint with a new investigator-initiated study at Mount Sinai. In this immunoprevention trial, the first patient, a high-risk smoker, has now been dosed with nadunolimab. Third, we published new scientific data reinforcing nadunolimab's mechanistic rationale in PDAC. These findings, published by JCI Insight in collaboration with the Sylvester Comprehensive Cancer Center at the University of Miami. Further, these findings validate IL1RAP as both a therapeutic target and a potential predictive biomarker. Strengthening our scientific and competitive positioning in PDAC. Finally, and perhaps most notably, we saw early but highly encouraging results from our ongoing investigator-initiated phase 1b/2a trial in high-risk myelodysplastic syndromes, or MDS, and acute myeloid leukemia, or AML. All five evaluable patients in the high-risk MDS cohort achieved complete remission, and at the reported data cut, with the sixth patient still pending, this is a signal that we view as clinically meaningful and a potential new value driver for nadunolimab. Taken together, these developments show Cantargia executing on multiple fronts at once, strengthening our financial position, advancing nadunolimab through key clinical milestones, and expanding the scientific case of IL1RAP as a validated target across both solid tumors and hematologic malignancies. This slide provides an overview of our IL1RAP-focused pipeline, and I've highlighted the initiatives that are currently the most active. Nadunolimab remains our lead oncology asset in PDAC. We are advancing our planned combination study with the KRAS inhibitor daraxonrasib, positioning nadunolimab within a rapidly evolving PDAC treatment landscape. As new agents and combination approaches reshape the standard of care in hematologic malignancies, specifically MDS and AML. The program is being run as an investigator-initiated study at MD Anderson Cancer Center, funded by the U.S. Department of Defense. This we see as a third-party validation of the underlying science that comes at no additional cost for us beyond nadunolimab.
We're building our broader IL1RAP platform that includes CANxx, our proprietary engine for developing unique IL1RAP antibodies, as well as IL1RAP know-how and our CAN14 bispecific antibody program in autoimmune diseases, which is the program that has advanced the most. We have still CAN10. As an important part of our autoimmune franchise, CAN10, as you all know, is partnered with Otsuka, which is funding its continued development following the 2025 acquisition. The key takeaway of this slide is that Cantargia is not a single-asset company.
We're building a focused but broad IL1RAP antibody platform with multiple shots on goal across both oncology and autoimmune diseases. And importantly, several of these programs are funded or partnered by third parties, which extends our capital efficiency.
Let us now move into the oncology part of the presentation. In oncology, our focus is on the diseases where IL1RAP biology may be particularly relevant and where there is a significant unmet medical need. The two main areas I will discuss today are PDAC, MDS, and AML. Next slide. We will start with PDAC. One of the most aggressive and difficult-to-treat forms of cancer. PDAC remains a disease with very high unmet medical need, and Cantargia's strategy is to position nadunolimab in combinations where IL1RAP blockade may complement other emerging treatment approaches. We are responding proactively to the recent second-line PDAC data for daraxonrasib in the Phase 3 RESOLUTE-302 trial. Daraxonrasib showed a meaningful improvement in overall survival versus chemotherapy, a result that is important for patients. And the patients have very few options at this stage of the disease. This reinforces our rationale for combining nadunolimab with a KRAS inhibitor. And here we outline our planned Phase 1b study evaluating the combination in second-line PDAC. The study is designed as an open-label phase one trial evaluating the safety and tolerability of nadunolimab combined with daraxonrasib in patients with metastatic PDAC who have previously progressed on first-line standard of care. The planned study population is approximately 15 patients. The proposed regimen pairs nadunolimab at 5 mg/kg every two weeks with daraxonrasib at 300 mg once daily. The primary objective is to determine safety and tolerability. Secondary objectives will include preliminary signs of clinical efficacy, with exploratory objectives covering inflammatory, immune, and tumor microenvironment-related parameters in both circulation and tumor tissue. The study is expected to be initiated in the first quarter of 2026, subject to regulatory approval and daraxonrasib availability. The rationale for combining nadunolimab with daraxonrasib rests on the interaction between IL1RAP-driven inflammatory signaling and KRAS-driven tumor biology. KRAS fuels IL-1-dependent tumor inflammation, and IL-1 signaling through IL1RAP contributes to the self-sustaining inflammatory circuit in the tumor microenvironment involving both myeloid cells and cancer-associated fibroblasts. Importantly, nadunolimab acts through a pathway that runs parallel to rather than overlapping with the KRAS pathway, offering a complementary mechanism of action alongside RAS inhibition. Together, this builds a strong biologic rationale to explore whether IL1RAP blockade with nadunolimab can add further benefit in combination with a KRAS inhibitor. The scientific rationale is further supported by survival data showing that high IL1RAP RNA expression in PDAC tumors correlates with poor survival. Importantly, this relationship holds not only across all comers, but specifically also in patients with KRAS mutations, indicating that IL1RAP's prognostic value is not diminished by RAS status. For us, this is a meaningful data point.
It reinforces IL1RAP not only as a therapeutic target, but as a marker of aggressive tumor biology in PDAC, including the KRAS-mutated patient, which is the most relevant patient population to our planned combination with daraxonrasib. Nadunolimab and Daraxonrasib have complementary mechanisms of action, each addressing a different compartment of the tumor. Nadunolimab targets IL1RAP, acting on both the immune compartment by dampening IL-1 driven inflammatory signaling along myeloid and T cells, and the stromal compartment, where it may help address the dense, drug-limiting stroma characteristic of PDAC. Daraxonrasib, by contrast, targets Ras signaling directly within the tumor cells, where KRAS mutation is a key driver of disease progression. By combining these approaches alongside standard chemotherapy, the aim is to address multiple interacting components of PDAC biology rather than a single pathway in isolation. It is, therefore, not simply an empirical combination. It is based on a mechanistic hypothesis that blocking IL1RAP-driven inflammation and stromal effects may complement Ras pathway inhibition and potentially improve the outcomes for a patient population with very limited treatment options. I will now move from solid tumors to hematologic malignancies, specifically MDS and AML. This is an increasingly important area for Cantargia because IL1RAP biology is highly relevant in leukemic stem cells, and because the medical need in high-risk MDS and AML remains substantial. The ongoing investigator-initiated phase 1b/2 study is evaluating Nadunolimab in this specific patient population. A study at M.D. MD Anderson Cancer Center is evaluating nadunolimab in exactly this patient population. The principal investigator is Gautam Borthakur, and the study is supported by a grant of the U.S. Department of Defense. The study started in 2025. It includes two arms. The study includes two arms. Arm one enrolls patients with intermediate, high, or very high-risk MDS, and arm two enrolls patients with relapsed or refractory AML in first or second salvage. The phase one part has been completed, and the study is progressing into phase two. Nadunolimab with azacitidine or with azacitidine and venetoclax was generally well tolerated across both patient groups with an acceptable safety profile, most notably in the high-risk MDS cohort. Five out of five evaluable patients achieved complete remissions, with the sixth patient pending at the January 2026 data cut. These are early data, and the numbers of patients are still small, but the results are highly encouraging and support continued evaluation of nadunolimab in high-risk MDS. The clinical observation in this study, as shown here, is also reinforcing IL1RAP as a high-risk marker. IL1RAP is overexpressed in leukemic diseases and is linked to adverse inflammatory and signaling profiles in AML. Higher IL1RAP expression has been associated with poor outcomes, as we saw in our PDAC clinical studies. This provides rationale for targeting IL1RAP in patients with particular high unmet need, including high-risk MDS and AML. Now, IL1RAP sits at the center of the disease biology in both MDS and AML. At the level of the leukemic stem cell itself, MDS originates from IL1RAP-positive leukemic stem cells in the bone marrow, which produce immature, non-functional blood cells. In MDS, blasts remain below 20% of the bone marrow cells, and MDS is classified into low, intermediate, and high-risk categories. High-risk MDS is likely to transform into AML within two years. AML, in turn, is defined by blast cells exceeding 20% of the bone marrow, also arising from IL1RAP-positive leukemic stem cells. It remains a highly lethal blood cancer, with survival rates of only 10% to 30% after five years. Current treatment relies on chemotherapy and stem cell transplantation. Transplantation, with only a limited number of targeted therapies available for specific genetic subtypes. Importantly, high I. Higher IL1RAP expression is also independently associated with poor survival in AML, reinforcing its relevance not just as a disease driver but also as a clinically meaningful biomarker, much like the one we discussed for PDAC. In short, IL1RAP is closely related to the biology of both diseases at the stem cell level, which is exactly what makes it an attractive therapeutic target. A central challenge in MDS and AML is that leukemic stem cells can escape current chemotherapy strategies, thereby creating a reservoir for relapse. There is therefore a very strong medical need for therapies that target leukemic stem cells with specificity. IL1RAP fits that need. It is expressed on leukemic stem cells in AML and high-risk MDS, but not on normal hematopoietic stem cells. Nadunolimab targets IL1RAP in these leukemic stem cells, aiming to block proliferation and label cells for killing through antibody-dependent cellular cytotoxicity, or ADCC. This is core to the therapeutic concept, targeting disease-driven cells through a mechanism that is biologically differentiated from standard cytotoxic treatment. High-risk MDS represents a meaningful clinical and commercial opportunity for Cantargia. Globally, there are approximately 400,000 MDS patients, with high-risk patients representing around 35% of that population. Median survival in high-risk MDS is just 1 to 2 years. Current backbone treatment relies on hypomethylating agents or HMA's such as Vidaza, Dacogen, and Inqovi. Yet a significant unmet need remains. Stem cell transplantation is the only intervention with curative potential, but 70% of patients are not eligible for this. In addition, about half of the patients do not respond to HMA therapy, and effective post-relapse treatment options are lacking. Median overall survival in this setting with HMA-resistant disease is only 5 to 6 months. Resistance is only 5 to 6 months. The global high-risk MDS population is approximately 150,000 patients, and this market is estimated to be approximately $4.5 billion in 2028 and projected to grow to around $11.2 billion in 2034. For Cantargia, the strategic case is clear: high-risk MDS combines a strong biologic rationale in IL1RAP, targeting a high unmet need and a potentially significant market opportunity. Beyond nadunolimab. We are also advancing our next-generation IL1RAP therapeutics; CANxx is our program for new therapeutics and reagents built on our deep knowledge of IL1RAP and its role in disease biology. That knowledge base includes a library of approximately 200 high-affinity antibodies. Now reaching up to 500 anti-IL1RAP antibodies and clones developed within the platform. These antibodies bind to different domains of IL1RAP and carry different functional properties, giving us a broad toolkit to pursue multiple therapeutic strategies rather than a single mechanism of action. CAN10 was the first program to originate from this platform, and CAN14 is the second, adding new features to IL1RAP blockade. CAN14 is the second, adding new features to IL1RAP blockade. Together, they illustrate the broader value of our IL1RAP platform.
And we are not developing a single antibody. We are building a pipeline of differentiated, IL1RAP-directed therapeutic strategies. Our next-generation strategy builds on the observation that IL1RAP blockade is a potent way to block inflammation in preclinical and translational ex vivo models. We are exploring bispecific antibodies, which can add new functionalities to IL1RAP blockade and be tailored to specific diseases. We're also exploring antibody-drug conjugates, or ADCs, which combine cytotoxicity and IL1RAP targeting in one single molecule to increase efficacy and concentrate the effect. The broader rationale holds across both approaches. IL1RAP is expressed in a large number of solid and hematologic tumors with limited expression in normal tissue.
This concludes our operational and pipeline section.
I will now hand over to Patrik Renblad, who will take us through the financial results of the quarter and the first six months. Patrik, over to you.